PCV chemotherapy for recurrent glioblastoma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16505319.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Brain Neoplasms
- Glioblastoma